Great post Oracle, well researched and the payments look well achievable. 12/5/2016 Aduro biotech announces first patient dosed in Phase 1 study of ADU-S100 for the treatment of cutaneously accessible tumours. This achievement activated a $35m milestone payment from it,s partner Novartis. In March 2015 Aduro entered into a collaboration with Novartis and received a $200m upfront payment with an additional $50m equity investment to further progress research. Aduro is also eligible to receive $465m in development and regulatory milestone payments subject to all stated objectives of the collaboration being achieved. Both companies will share profits, if any, in the USA, Japan and major European countries, and Aduro will receive further ROW sales royalties. Just what Tim, Sareum and all we pi,s could do with. A nice sized slice of a very big pie. Be healthy, people.
Alizyme.....bad memories. This was my first foray into AIM and I lost a packet because the company ran out of money. Don't they all! My last recollection of Cetilistat is that it gave everyone the Ben Guns.
I hope Sareum doesn't turn out to be the usual Dog as I would like to get my money back asap. My average is about 1.62p and I've been trapped here for years like many other suckers.
Tim said in 2015 that he is looking to license in or during phase 1. He said this specifically. That the upfront payments are usually around £15 to £20 million and the milestone payments ranged in the hundreds of millions, something say from £200 to £300 million thereabouts. (According to his graph)
The risk of failure at phase 1 is around 20% and rises to 60% in phase 2. As to why he's not really interested in phase 2. Looking at the graph he presented, the phases after 2, the risk drops sharply, btw.
He goes on to mention that big pharma's are at a loss due to patents. Patent expiry estimated to cost big pharma's something in the region of £290B by 2018. That to fill their pipeline they are increasingly looking at small biotech companies to licence from. This process has risen from 30% to 50% in a decade or so. Prior to this he mentions Astrazeneca and GSK ( he used to work there) being the sharks and dare I say Sareum is a fat juicy goldfish, that's getting fatter every day (fact, not ramping)
Also, one of the world's biggest selling drugs Humira, was licensed by a big pharma Abbot Laboratories from a small Cambridge based biotech like Sareum. And now sells in the region of $8 Billion per year. https://en.m.wikipedia.org/wiki/Adalimumab
Tim was the inventor of Cetilistat, a drug for obesity while he was working at Cambridge Discovery Chemistry. Cetilistat has completed Phase 1 and 2 trials in the West and is currently in Phase 3 trials in Japan where it is partnered with Takeda. Norgina BV has now acquired the full global rights to cetilistat from Alizyme (Cetilistat was this companies last remaining drug) after the latter went into administration http://www.drugdevelopment-technology.com/projects/cetilistat/
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.